Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide

N. Irwin, P.L. McClean, R.S. Cassidy, F.P.M. O'Harte, Brian Green, V.A. Gault, Patrick Harriott, P.R. Flatt

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)

Abstract

Background The two major incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are being actively explored as anti-diabetic agents because they lower blood glucose through multiple mechanisms. The rapid inactivation of GIP and GLP-1 by the ubiquitous enzyme, dipeptidyl peptidase IV (DPP IV) makes their biological actions short-lived, but stable agonists such as N-acetylated GIP (N-AcGIP) and exendin(1-39)amide have been advocated as stable and specific GIP and GLP-1 analogues.
Original languageEnglish
Pages (from-to)572-579
Number of pages8
JournalDIABETES-METABOLISM RESEARCH AND REVIEWS
Volume23
Issue number7
DOIs
Publication statusPublished - Oct 2007

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide'. Together they form a unique fingerprint.

Cite this